The short version of thymalfasin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
In November 1993, relator Robert Marena, an SKB employee, filed a qui tam action against GlaxoSmithKline in the United States District Court for the Eastern District of Pennsylvania. His complaint contained eight separate claims under the False Claims Act. Merena's complaint alleged that SKB had defrauded the government by, inter alia, billing for tests that were not performed, double billing, paying illegal kickbacks to health care professionals, and adding tests to "automated chemistry" profiles and then separately billing for those tests. After a month, relator Glenn Grossenbacher, an attorney, filed a second qui tam action against GlaxoSmithKline in the United States District Court for the Western District of Texas. Relators Kevin Spear, Jack Dowden, and the Berkeley Community Law Center (collectively, "the Spear relators") followed in February 1995 with a suit in the Northern District of California. The courts in Texas and California transferred these actions to the Eastern District of Pennsylvania for consolidation with the Merena case. After Merena's action was filed, the government commenced an investigation into a series of new claims that were not part of its original investigation. At the same time, the government continued to pursue the original "automated chemistry" investigation that it had begun after the 1992 settlement with National Health Laboratories. Later in August 1995, the government began formal settlement negotiations with GlaxoSmithKline.
The problem of minimizing ET is an NP-hard problem. Even though the class of problems is NP-hard, in practice many instances of protein design can be solved exactly or optimized satisfactorily through heuristic methods.
== Clinical Relevance == MMP-13 has long been a protein of interest in the context of osteoarthritis and rheumatoid arthritis. The role of MMP-13 has also been thoroughly examined in atherosclerosis, specifically in potentially reducing the collagen content of the fibrous cap.
Von Willebrand factor is normally synthesized in the endoplasmic reticulum of endothelial cells lining blood vessels (and also in megakaryocytes), and it is then packaged into multimers (many strands of vWF connected by disulfide bonds) by the Golgi and stored in Weibel-Palade bodies as a helical spiral of multiple multimers. When vWF is secreted by endothelial cells, the multimers are cleaved by the enzyme ADAMTS13 and vWF circulates in the plasma in a coiled and inactive form. When there is damage to a blood vessel (due to trauma or other factors) collagen under the blood vessel lining is exposed. When vWF comes into contact with exposed collagen it uncoils and binds to the collagen. Circulating platelets bind to vWF using their GpIb-alpha surface protein which binds to a specific area on the uncoiled vWF strand (The A1 domain binding site). Upon binding, the platelets become activated and irregularly shaped which attracts more platelets to the area of vascular damage to form a platelet plug in the blood vessel wall and stop the bleeding. In VWD, vWF is either deficient (type 1 disease), dysfunctional (type 2 disease), or is completely absent (the severe type 3 disease) leading to dysfunction in the above mechanism to stop bleeding. Circulating vWF also binds to coagulation factor VIII preventing it from being degraded. Factor VIII is involved in the coagulation cascade to also prevent excessive bleeding. Von Willebrand factor is mainly active in conditions of high blood flow and shear stress.
Sources: en.wikipedia.org
Georgia joined the Iraq war as part of the United States-led coalition in August 2003. By 2008, Georgia had deployed 2,300 troops in Iraq, becoming the third largest contributor to the coalition forces in the Iraq War. In addition, the country provided a battalion of approximately 550 troops to the United Nations Assistance Mission in Iraq. All Georgian troops were withdrawn from Iraq amid the Russia–Georgia war in August 2008. Georgia suffered five fatal casualties in Iraq.
In July 2023, the paper announced it will reduce its print schedule to three days a week: Tuesday, Thursday and Saturday. Also, the newspaper will transition from carrier to postal delivery. In September 2024, Napa Valley Publishing, which publishes the paper, was sold by Lee Enterprises to Hoffmann Media Group.
=== Dentistry === Calcium sulfate has a long history of use in dentistry. It has been used in bone regeneration as a graft material and graft binder (or extender) and as a barrier in guided bone tissue regeneration. It is a biocompatible material and is completely resorbed following implantation. It does not evoke a significant host response and creates a calcium-rich milieu in the area of implantation.
=== Influence of Vladimir Cerrón === Vladimir Cerrón is the General Secretary of Free Peru, who represents the Marxist–Leninist faction of the party. Cerrón was previously the governor of Junín, but was convicted for corruption and given a suspended sentence. Cerrón has repeatedly denied such charges, stating that he's a victim of lawfare and political persecution. The indictment prevents Cerrón from running for public office. During the 2021 Peruvian general election, Castillo distanced himself from Cerrón, saying that Cerrón "will not even be a doorman in any of the institutions of the State." However, Castillo has been accused of appointing government officials and ministers who are close to Cerrón. These include the appointment of Waldemar Cerrón, Vladimir's brother, as Free Peru's spokesman in Congress, despite Waldemar being investigated for money laundering. Waldemar has also been under investigation in Los Dinámicos del Centro, an alleged criminal organization that's investigated for money laundering. The investigations also include Vladimir and then Prime Minister Bellido. Vladimir has accused the investigations of being political persecution. Later, a number of alleged members of Los Dinámicos del Centro escaped from the country. Prime Minister Mirtha Vásquez stated that they have been included in Peru's registry of most wanted fugitives.
=== Harvard === In 1936, his spectroscopic skills won him a fellowship and substantial grant at Harvard University. His work there led to the 1938 publication of measurements of the relative abundance of the isotopes of uranium, measurements that were used by Fritz Houtermans and Arthur Holmes in the 1940s to estimate the age of the Earth.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.